Moody’s upgrades Agnico Eagle’s rating to A3 on debt reduction
ROCKVILLE, MD—Padmanabh P. Bhatt, Senior Vice President of Intellectual Property and Chief Scientific Officer at Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a company that InvestingPro data shows maintains impressive gross profit margins of 89%, reported a recent transaction involving the sale of company stock. According to a filing with the Securities and Exchange Commission, Bhatt sold 9,477 shares of common stock on February 4, 2025. The shares were sold at an average price of $39.70, resulting in a total transaction value of $376,236. The transaction occurs as the stock trades near its 52-week high of $40.24, having gained over 43% in the past six months.
This transaction follows an exercise of stock options, where Bhatt acquired 9,477 shares at an exercise price of $29.61 each, bringing the total cost of this acquisition to $280,613. After these transactions, Bhatt’s direct ownership in the company stands at 10,149 shares.
The stock sale was executed under a pre-arranged trading plan, often established to avoid potential insider trading concerns. The weighted average sale price of the shares was between $39.61 and $39.90, as disclosed in the filing.
In other recent news, Supernus Pharmaceuticals has been the subject of several significant developments. The company recently received FDA approval for ONAPGO, a new treatment for advanced Parkinson’s disease motor fluctuations. This novel subcutaneous apomorphine infusion device is expected to be available in the U.S. by the second quarter of 2025. The approval came after a Phase 3 clinical trial demonstrated significant reductions in daily OFF time and increases in GOOD ON time for patients.
Analysts at Stifel maintained their Hold rating on Supernus, keeping their price target steady at $38.00, while TD Cowen raised their price target to $44.00 from $43.00, maintaining a Buy rating. Both firms acknowledged the potential impact of ONAPGO on Supernus’ Parkinson’s disease portfolio.
In addition to ONAPGO, Supernus announced an FDA-approved label update for its ADHD treatment, Qelbree. The updated label now includes new pharmacodynamic data and lactation study results. Despite these developments, analysts from both Stifel and TD Cowen pointed out that Qelbree remains the primary growth driver for Supernus. These are recent developments in the company’s journey to strengthen its portfolio and ensure long-term sustainability within its specialized therapeutic areas.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.